insulin detemir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4985	169148-63-4

Description:

Molecule	Description
Synonyms: insulin detemir levemir insulin detemir recombinant insulin detemir [rDNA origin] NN304 NN 304 NN-304	A recombinant long-acting insulin and hypoglycemic agent in which a MYRISTIC ACID is conjugated to a LYSINE at position B29. It is used to manage BLOOD GLUCOSE levels in patients with DIABETES MELLITUS. Molecular weight: 5916.89 Formula: C267H402N64O76S6 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 2252.82 ALOGS: ROTB: None

Molecule

Description

Synonyms:

insulin detemir
levemir
insulin detemir recombinant
insulin detemir [rDNA origin]
NN304
NN 304
NN-304

A recombinant long-acting insulin and hypoglycemic agent in which a MYRISTIC ACID is conjugated to a LYSINE at position B29. It is used to manage BLOOD GLUCOSE levels in patients with DIABETES MELLITUS.

Molecular weight: 5916.89
Formula: C267H402N64O76S6
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 2252.82
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
40	U	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 1, 2004	EMA
June 16, 2005	FDA	NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood glucose increased	690.73	13.23	417	23711	83339	63381555
Hypoglycaemia	528.47	13.23	312	23816	59753	63405141
Diabetic ketoacidosis	384.15	13.23	177	23951	20328	63444566
Blood glucose decreased	208.34	13.23	118	24010	20834	63444060
Hyperglycaemia	185.05	13.23	142	23986	41725	63423169
Diabetes mellitus inadequate control	171.79	13.23	93	24035	15033	63449861
Lactic acidosis	162.97	13.23	127	24001	38160	63426734
Gangrene	137.38	13.23	60	24068	6063	63458831
Glycosylated haemoglobin increased	131.86	13.23	73	24055	12325	63452569
Blood glucose fluctuation	126.48	13.23	52	24076	4524	63460370
Arterial occlusive disease	110.16	13.23	51	24077	5907	63458987
Ketoacidosis	105.09	13.23	45	24083	4333	63460561
Acute kidney injury	86.88	13.23	258	23870	263157	63201737
Hypoglycaemic unconsciousness	86.28	13.23	25	24103	752	63464142
Exposure during pregnancy	84.37	13.23	184	23944	155363	63309531
Drug ineffective	83.07	13.23	171	23957	1044594	62420300
Drug intolerance	78.17	13.23	12	24116	308649	63156245
Hypoglycaemic coma	73.68	13.23	30	24098	2545	63462349
Diabetic retinopathy	69.64	13.23	28	24100	2299	63462595
Treatment failure	63.07	13.23	3	24125	199040	63265854
Angina pectoris	62.98	13.23	67	24061	30011	63434883
Injection site mass	60.75	13.23	53	24075	18603	63446291
Blood glucose abnormal	58.99	13.23	37	24091	7855	63457039
Alopecia	57.87	13.23	28	24100	337508	63127386
Premature delivery	57.38	13.23	64	24064	30217	63434677
Carotid artery thrombosis	55.05	13.23	25	24103	2769	63462125
Insulin resistance	54.12	13.23	18	24110	860	63464034
Anti-insulin antibody positive	51.06	13.23	11	24117	92	63464802
Neurologic neglect syndrome	49.39	13.23	23	24105	2698	63462196
Infusion related reaction	49.22	13.23	16	24112	245505	63219389
Cerebrovascular accident	47.76	13.23	118	24010	107906	63356988
Joint swelling	46.56	13.23	34	24094	327632	63137262
Systemic infection	45.63	13.23	26	24102	4634	63460260
Arthropathy	44.15	13.23	17	24111	234775	63230119
Pancreatitis	42.64	13.23	71	24057	48984	63415910
Infective pulmonary exacerbation of cystic fibrosis	41.34	13.23	31	24097	8786	63456108
Injection site urticaria	39.93	13.23	37	24091	14036	63450858
Visceral congestion	38.02	13.23	11	24117	329	63464565
Cataract	37.36	13.23	73	24055	56980	63407914
Hypoglycaemia neonatal	37.22	13.23	14	24114	961	63463933
Therapeutic product effect decreased	34.67	13.23	15	24113	193172	63271722
Foetal exposure during pregnancy	34.35	13.23	51	24077	31911	63432983
Hepatic enzyme increased	34.31	13.23	17	24111	202311	63262583
Hypoglycaemic seizure	34.01	13.23	11	24117	481	63464413
Pre-eclampsia	33.94	13.23	28	24100	9105	63455789
Gastric disorder	33.71	13.23	55	24073	37314	63427580
Anuria	33.70	13.23	32	24096	12519	63452375
Personality disorder	33.11	13.23	23	24105	5788	63459106
Injection site erythema	32.76	13.23	87	24041	83087	63381807
Injection site pruritus	32.34	13.23	60	24068	45056	63419838
Musculoskeletal stiffness	32.08	13.23	15	24113	184603	63280291
Discomfort	31.65	13.23	12	24116	167362	63297532
Completed suicide	30.06	13.23	9	24119	145664	63319230
Product use issue	29.87	13.23	24	24104	220496	63244398
Diabetic neuropathy	28.16	13.23	18	24110	3946	63460948
Blood ketone body	27.87	13.23	6	24122	50	63464844
Fall	27.49	13.23	248	23880	392086	63072808
Abdominal discomfort	27.48	13.23	50	24078	320835	63144059
Hemiplegia	27.40	13.23	25	24103	9298	63455596
Premature baby	26.59	13.23	36	24092	20699	63444195
Arthralgia	26.49	13.23	119	24009	569591	62895303
Motor dysfunction	26.19	13.23	26	24102	10735	63454159
Hyperkalaemia	25.86	13.23	61	24067	54142	63410752
Sensory loss	25.41	13.23	25	24103	10213	63454681
Anti-insulin antibody	24.25	13.23	5	24123	33	63464861
Rhonchi	24.23	13.23	14	24114	2562	63462332
Coordination abnormal	24.20	13.23	28	24100	13745	63451149
Vomiting	24.07	13.23	321	23807	559296	62905598
Adjustment disorder	24.00	13.23	15	24113	3163	63461731
Skin haemorrhage	23.85	13.23	24	24104	10070	63454824
Affect lability	23.62	13.23	25	24103	11126	63453768
Hypoglycaemia unawareness	23.23	13.23	6	24122	116	63464778
Pancreatitis acute	23.18	13.23	39	24089	27127	63437767
Duodenal ulcer perforation	22.96	13.23	3	24125	87206	63377688
General physical health deterioration	22.39	13.23	142	23986	201260	63263634
Gestational hypertension	22.37	13.23	13	24115	2404	63462490
Anti-insulin antibody increased	21.98	13.23	5	24123	55	63464839
Therapeutic product effect incomplete	21.97	13.23	10	24118	125046	63339848
Impaired healing	21.77	13.23	6	24122	102536	63362358
Treatment noncompliance	21.16	13.23	45	24083	37280	63427614
Lower respiratory tract infection	21.12	13.23	12	24116	132295	63332599
Blood insulin decreased	21.07	13.23	4	24124	16	63464878
Neonatal anoxia	20.63	13.23	3	24125	0	63464894
Increased insulin requirement	20.42	13.23	5	24123	77	63464817
Blood pressure increased	20.38	13.23	118	24010	161944	63302950
Anaemia	20.28	13.23	185	23943	293245	63171649
Infection	20.24	13.23	35	24093	229138	63235756
Product administration error	20.24	13.23	33	24095	22364	63442530
Chest discomfort	20.12	13.23	89	24039	109880	63355014
Pain	19.88	13.23	183	23945	740445	62724449
Upper respiratory tract irritation	19.75	13.23	6	24122	213	63464681
Palpitations	19.68	13.23	90	24038	112680	63352214
Sinus congestion	19.59	13.23	29	24099	18094	63446800
Diabetic nephropathy	19.51	13.23	10	24118	1444	63463450
Diabetes mellitus	18.64	13.23	55	24073	55755	63409139
Altered state of consciousness	18.64	13.23	34	24094	25196	63439698
Acute myocardial infarction	18.52	13.23	39	24089	32085	63432809
Extradural haematoma	17.92	13.23	10	24118	1712	63463182
Euglycaemic diabetic ketoacidosis	17.40	13.23	13	24115	3661	63461233
Injection site rash	17.39	13.23	28	24100	18781	63446113
Cardiac death	17.32	13.23	7	24121	582	63464312
Dehydration	17.30	13.23	119	24009	173235	63291659
Diabetic retinal oedema	17.30	13.23	6	24122	326	63464568
Febrile neutropenia	17.17	13.23	12	24116	118437	63346457
Multiple lentigines syndrome	17.17	13.23	5	24123	153	63464741
Irritable bowel syndrome	17.16	13.23	5	24123	82407	63382487
Asphyxia	17.05	13.23	16	24112	6165	63458729
Injection site nodule	16.91	13.23	13	24115	3822	63461072
Asthenia	16.85	13.23	221	23907	383383	63081511
Sneezing	16.68	13.23	27	24101	18191	63446703
Renal impairment	16.53	13.23	72	24056	88283	63376611
Pallor	16.35	13.23	36	24092	30532	63434362
Neutropenia	16.12	13.23	26	24102	174979	63289915
Respiratory tract congestion	15.74	13.23	26	24102	17806	63447088
Renal failure	15.66	13.23	87	24041	117565	63347329
Metabolic acidosis	15.61	13.23	45	24083	45024	63419870
Aphasia	15.58	13.23	37	24091	32963	63431931
Hemiparesis	15.49	13.23	30	24098	23252	63441642
Stomatitis	15.40	13.23	18	24110	138707	63326187
Diabetic metabolic decompensation	15.31	13.23	9	24119	1701	63463193
Abortion spontaneous	15.28	13.23	46	24082	47149	63417745
Diabetic gangrene	14.94	13.23	3	24125	17	63464877
Macular oedema	14.64	13.23	12	24116	3865	63461029
C-reactive protein increased	14.53	13.23	9	24119	94698	63370196
Urogenital haemorrhage	14.41	13.23	5	24123	272	63464622
Sinus disorder	14.38	13.23	30	24098	24523	63440371
Drug level above therapeutic	14.35	13.23	13	24115	4792	63460102
Blood cholesterol increased	14.34	13.23	9	24119	94023	63370871
Jaundice neonatal	14.29	13.23	7	24121	918	63463976
Off label use	14.29	13.23	176	23952	674286	62790608
Pancreatic carcinoma	14.24	13.23	16	24112	7612	63457282
Liver injury	13.90	13.23	3	24125	60517	63404377
Paraplegia	13.89	13.23	10	24118	2662	63462232
Cataract subcapsular	13.87	13.23	6	24122	592	63464302
Vitreous haemorrhage	13.80	13.23	9	24119	2041	63462853
Shock hypoglycaemic	13.78	13.23	4	24124	121	63464773
Chronic kidney disease	13.54	13.23	43	24085	45355	63419539
Wrong product administered	13.42	13.23	14	24114	6127	63458767
Myocardial infarction	13.38	13.23	74	24054	99819	63365075
Decreased insulin requirement	13.36	13.23	4	24124	135	63464759
Cystoid macular oedema	13.34	13.23	8	24120	1567	63463327
Adenocarcinoma pancreas	13.28	13.23	7	24121	1071	63463823

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	440.52	13.16	298	17372	54342	34884919
Blood glucose increased	314.47	13.16	264	17406	66454	34872807
Diabetic ketoacidosis	175.87	13.16	111	17559	17921	34921340
Diabetes mellitus inadequate control	157.20	13.16	93	17577	13371	34925890
Blood glucose decreased	115.51	13.16	76	17594	13161	34926100
Blood glucose fluctuation	90.08	13.16	43	17627	4001	34935260
Hypoglycaemic coma	67.11	13.16	30	17640	2401	34936860
Hypoglycaemic unconsciousness	66.39	13.16	22	17648	776	34938485
Glycosylated haemoglobin increased	66.18	13.16	51	17619	11309	34927952
Anti-insulin antibody positive	60.25	13.16	15	17655	183	34939078
Hyperglycaemia	58.25	13.16	85	17585	39395	34899866
Foetal disorder	57.81	13.16	20	17650	806	34938455
Toxicity to various agents	55.96	13.16	16	17654	200346	34738915
Premature baby	54.39	13.16	58	17612	19575	34919686
General physical health deterioration	52.38	13.16	163	17507	128106	34811155
Pancreatic carcinoma metastatic	49.91	13.16	26	17644	2914	34936347
Neutropenia neonatal	48.91	13.16	17	17653	695	34938566
Foetal exposure during pregnancy	46.31	13.16	75	17595	38026	34901235
Blood glucose abnormal	39.74	13.16	29	17641	5923	34933338
Hypoglycaemic seizure	39.30	13.16	12	17658	323	34938938
Drug abuse	38.71	13.16	3	17667	99093	34840168
Injection site pruritus	37.75	13.16	30	17640	6953	34932308
Injection site mass	36.97	13.16	29	17641	6597	34932664
Injection site erythema	33.88	13.16	41	17629	15858	34923403
Ketoacidosis	33.72	13.16	23	17647	4220	34935041
Pancreatitis chronic	32.93	13.16	18	17652	2222	34937039
Acute kidney injury	32.52	13.16	264	17406	304724	34634537
VACTERL syndrome	31.60	13.16	7	17663	49	34939212
Vomiting projectile	31.22	13.16	12	17658	654	34938607
Pancreatitis	30.08	13.16	63	17607	38828	34900433
Diabetic neuropathy	29.27	13.16	21	17649	4176	34935085
Injection site urticaria	28.68	13.16	16	17654	2056	34937205
Low birth weight baby	28.60	13.16	27	17643	7878	34931383
Toe amputation	28.31	13.16	17	17653	2507	34936754
Diabetic metabolic decompensation	28.22	13.16	15	17655	1751	34937510
Drug ineffective	26.50	13.16	130	17540	456621	34482640
Product monitoring error	26.24	13.16	20	17650	4361	34934900
Dehydration	25.93	13.16	132	17538	129837	34809424
Diabetic gangrene	25.19	13.16	8	17662	246	34939015
Product prescribing error	25.00	13.16	43	17627	22884	34916377
Pancreatic carcinoma	24.12	13.16	26	17644	8875	34930386
Completed suicide	23.65	13.16	10	17660	98158	34841103
Diabetic retinopathy	22.37	13.16	13	17657	1804	34937457
Febrile neutropenia	22.04	13.16	22	17648	136827	34802434
Laryngeal leukoplakia	20.56	13.16	5	17665	55	34939206
Hypoglycaemia unawareness	20.42	13.16	6	17664	141	34939120
Adenocarcinoma pancreas	20.08	13.16	11	17659	1363	34937898
Oedema peripheral	20.04	13.16	116	17554	119696	34819565
Exposure to communicable disease	20.03	13.16	6	17664	151	34939110
Hemivertebra	19.96	13.16	6	17664	153	34939108
Anaemia vitamin B12 deficiency	18.03	13.16	7	17663	392	34938869
Diabetic foot	17.30	13.16	13	17657	2775	34936486
Infective pulmonary exacerbation of cystic fibrosis	16.93	13.16	19	17651	6782	34932479
Device failure	16.83	13.16	12	17658	2364	34936897
Hypoglycaemia neonatal	16.78	13.16	11	17659	1890	34937371
Injection site rash	16.60	13.16	15	17655	4138	34935123
Injection site pain	16.27	13.16	50	17620	38955	34900306
Product quality issue	16.07	13.16	30	17640	17005	34922256
Insulin-requiring type 2 diabetes mellitus	15.99	13.16	5	17665	146	34939115
Diabetes mellitus	15.89	13.16	56	17614	46817	34892444
Forced expiratory volume decreased	15.70	13.16	13	17657	3190	34936071
Funguria	15.56	13.16	4	17666	56	34939205
Injection site nodule	15.50	13.16	10	17660	1673	34937588
Injection site irritation	15.32	13.16	9	17661	1274	34937987
Diabetic coma	15.25	13.16	8	17662	909	34938352
Dyspnoea	15.22	13.16	271	17399	376511	34562750
Infusion related reaction	15.22	13.16	4	17666	53053	34886208
Syncope	14.93	13.16	88	17582	91363	34847898
Shock haemorrhagic	14.68	13.16	23	17647	11331	34927930
Diabetic foot infection	14.45	13.16	7	17663	672	34938589
Lack of application site rotation	14.27	13.16	4	17666	79	34939182
Urogenital infection fungal	14.24	13.16	3	17667	16	34939245
Pneumobilia	13.95	13.16	4	17666	86	34939175
Shock hypoglycaemic	13.46	13.16	4	17666	98	34939163
Injection site ulcer	13.29	13.16	5	17665	257	34939004

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	790.66	11.92	510	33743	101084	79609051
Blood glucose increased	620.63	11.92	461	33792	114514	79595621
Diabetic ketoacidosis	463.27	11.92	246	34007	33876	79676259
Diabetes mellitus inadequate control	268.75	11.92	153	34100	24111	79686024
Blood glucose decreased	201.85	11.92	131	34122	26103	79684032
Hyperglycaemia	199.24	11.92	195	34058	70140	79639995
Blood glucose fluctuation	150.16	11.92	68	34185	6614	79703521
Lactic acidosis	135.46	11.92	159	34094	70200	79639935
Ketoacidosis	127.77	11.92	64	34189	7790	79702345
Gangrene	125.45	11.92	66	34187	8898	79701237
Acute kidney injury	119.67	11.92	490	33763	518914	79191221
Glycosylated haemoglobin increased	119.06	11.92	84	34169	19176	79690959
Hypoglycaemic unconsciousness	117.91	11.92	36	34217	1147	79708988
Hypoglycaemic coma	111.92	11.92	50	34203	4710	79705425
Anti-insulin antibody positive	96.69	11.92	23	34230	273	79709862
Drug ineffective	85.47	11.92	214	34039	1080699	78629436
Arterial occlusive disease	84.77	11.92	50	34203	8406	79701729
Diabetic retinopathy	80.70	11.92	35	34218	3071	79707064
General physical health deterioration	79.16	11.92	279	33974	274959	79435176
Blood glucose abnormal	62.80	11.92	45	34208	10521	79699614
Injection site mass	60.94	11.92	58	34195	20126	79690009
Completed suicide	55.84	11.92	18	34235	245749	79464386
Drug intolerance	55.48	11.92	22	34231	264097	79446038
Pancreatitis	51.76	11.92	100	34153	68475	79641660
Infective pulmonary exacerbation of cystic fibrosis	50.81	11.92	43	34210	12808	79697327
Infusion related reaction	50.32	11.92	18	34235	230219	79479916
Carotid artery thrombosis	50.02	11.92	25	34228	3028	79707107
Hypoglycaemic seizure	49.18	11.92	17	34236	807	79709328
Diabetic neuropathy	47.69	11.92	31	34222	6185	79703950
Treatment failure	47.58	11.92	8	34245	170478	79539657
Exposure during pregnancy	46.48	11.92	121	34132	101011	79609124
Joint swelling	46.11	11.92	34	34219	288612	79421523
Pancreatic carcinoma metastatic	45.15	11.92	25	34228	3728	79706407
Angina pectoris	43.47	11.92	79	34174	51653	79658482
Neurologic neglect syndrome	42.37	11.92	22	34231	2885	79707250
Injection site urticaria	40.91	11.92	38	34215	12788	79697347
Contraindicated product administered	40.56	11.92	9	34244	157529	79552606
Cataract	40.22	11.92	85	34168	62035	79648100
Dehydration	37.78	11.92	208	34045	247979	79462156
Injection site pruritus	37.36	11.92	66	34187	42217	79667918
Insulin resistance	37.34	11.92	16	34237	1363	79708772
Diabetic metabolic decompensation	36.84	11.92	21	34232	3311	79706824
Arthropathy	36.78	11.92	15	34238	177096	79533039
Gastric disorder	36.44	11.92	61	34192	37372	79672763
Anti-insulin antibody	35.94	11.92	8	34245	69	79710066
Pancreatitis chronic	35.72	11.92	22	34231	3997	79706138
Drug abuse	33.42	11.92	14	34239	162677	79547458
Cerebrovascular accident	32.84	11.92	143	34110	155149	79554986
Alopecia	32.33	11.92	31	34222	231324	79478811
Diabetic gangrene	32.23	11.92	9	34244	208	79709927
Febrile neutropenia	32.23	11.92	31	34222	230968	79479167
Product prescribing error	32.17	11.92	64	34189	44749	79665386
Hypoglycaemia unawareness	31.40	11.92	9	34244	229	79709906
Injection site erythema	31.36	11.92	89	34164	78108	79632027
Toxicity to various agents	31.17	11.92	86	34167	421454	79288681
Hyperkalaemia	31.14	11.92	114	34139	114284	79595851
Glossodynia	30.78	11.92	4	34249	103333	79606802
Pancreatitis acute	29.96	11.92	66	34187	49538	79660597
Pericarditis	28.84	11.92	5	34248	104231	79605904
Musculoskeletal stiffness	28.74	11.92	20	34233	174988	79535147
Adenocarcinoma pancreas	28.53	11.92	15	34238	2018	79708117
Anaemia	28.38	11.92	304	33949	444711	79265424
Personality disorder	27.29	11.92	22	34231	6124	79704011
Euglycaemic diabetic ketoacidosis	27.26	11.92	23	34230	6821	79703314
Anti-insulin antibody increased	27.26	11.92	7	34246	116	79710019
Injection site nodule	26.93	11.92	18	34235	3762	79706373
Premature delivery	26.62	11.92	41	34212	23426	79686709
Product quality issue	26.22	11.92	50	34203	33890	79676245
Blood ketone body	26.17	11.92	7	34246	137	79709998
Systemic infection	25.66	11.92	26	34227	9726	79700409
Visceral congestion	25.58	11.92	11	34242	945	79709190
Off label use	25.55	11.92	258	33995	906957	78803178
Increased insulin requirement	24.35	11.92	7	34246	180	79709955
Anuria	24.31	11.92	37	34216	20926	79689209
Anaemia vitamin B12 deficiency	24.20	11.92	10	34243	778	79709357
Toe amputation	24.03	11.92	17	34236	3894	79706241
Therapeutic product effect decreased	24.02	11.92	21	34232	163842	79546293
Arthralgia	23.82	11.92	146	34107	571657	79138478
Diabetes mellitus	23.81	11.92	81	34172	78309	79631826
Hepatic enzyme increased	23.77	11.92	26	34227	182584	79527551
Vomiting	23.53	11.92	409	33844	665419	79044716
Syncope	23.14	11.92	144	34109	179305	79530830
Affect lability	22.57	11.92	26	34227	11233	79698902
Chronic kidney disease	22.46	11.92	71	34182	66083	79644052
Lower respiratory tract infection	22.25	11.92	14	34239	129206	79580929
Product monitoring error	22.09	11.92	23	34230	8883	79701252
Vomiting projectile	21.61	11.92	12	34241	1799	79708336
Laryngeal leukoplakia	21.28	11.92	5	34248	56	79710079
Skin haemorrhage	21.27	11.92	26	34227	11955	79698180
Infection	21.25	11.92	45	34208	241667	79468468
Discomfort	21.09	11.92	14	34239	125603	79584532
Device failure	20.84	11.92	19	34234	6242	79703893
Motor dysfunction	19.98	11.92	28	34225	14705	79695430
Diabetic coma	19.78	11.92	10	34243	1241	79708894
Sensory loss	19.60	11.92	26	34227	12965	79697170
Blood cholesterol increased	19.23	11.92	6	34247	83714	79626421
Rhonchi	19.10	11.92	15	34238	4021	79706114
Pre-eclampsia	18.95	11.92	19	34234	7022	79703113
Treatment noncompliance	18.58	11.92	57	34196	52211	79657924
Gestational hypertension	18.54	11.92	11	34242	1868	79708267
Dyspnoea	18.48	11.92	490	33763	856535	78853600
Diabetic foot	18.28	11.92	14	34239	3618	79706517
Hemiplegia	18.22	11.92	27	34226	14912	79695223
Neutropenia	18.19	11.92	63	34190	287647	79422488
Fall	18.09	11.92	302	33951	487327	79222808
Visual impairment	18.08	11.92	83	34170	92048	79618087
Upper respiratory tract irritation	17.95	11.92	6	34247	257	79709878
Asthenia	17.93	11.92	314	33939	511375	79198760
Injection site irritation	17.76	11.92	14	34239	3776	79706359
Product administration error	17.70	11.92	41	34212	31805	79678330
Injection site rash	17.13	11.92	29	34224	17925	79692210
Adjustment disorder	17.09	11.92	14	34239	3986	79706149
Product use in unapproved indication	17.08	11.92	53	34200	250306	79459829
Accidental underdose	16.96	11.92	8	34245	854	79709281
Metabolic acidosis	16.68	11.92	75	34178	82454	79627681
Coordination abnormal	16.57	11.92	28	34225	17284	79692851
Insulin-requiring type 2 diabetes mellitus	16.38	11.92	5	34248	159	79709976
Diabetic nephropathy	16.26	11.92	12	34241	2935	79707200
Product dispensing error	16.22	11.92	24	34229	13239	79696896
Diabetic retinal oedema	16.12	11.92	6	34247	353	79709782
Type 1 diabetes mellitus	15.62	11.92	17	34236	6902	79703233
Chest discomfort	15.49	11.92	107	34146	137937	79572198
Therapeutic product effect incomplete	15.49	11.92	23	34230	141622	79568513
Duodenal neoplasm	15.43	11.92	4	34249	69	79710066
Multiple lentigines syndrome	15.41	11.92	5	34248	195	79709940
Insulin autoimmune syndrome	15.04	11.92	6	34247	426	79709709
Cellulitis	14.99	11.92	89	34164	108971	79601164
Sinus congestion	14.99	11.92	29	34224	19867	79690268
Nonreassuring foetal heart rate pattern	14.73	11.92	3	34250	16	79710119
Lack of application site rotation	14.51	11.92	4	34249	88	79710047
Intentional product use issue	14.50	11.92	27	34226	152085	79558050
Pancreatic carcinoma	14.40	11.92	23	34230	13554	79696581
Blood insulin decreased	14.29	11.92	3	34250	19	79710116
Urogenital infection fungal	14.29	11.92	3	34250	19	79710116
Injection site pain	14.19	11.92	100	34153	129738	79580397
Hemiparesis	14.11	11.92	39	34214	33694	79676441
Sneezing	13.99	11.92	28	34225	19655	79690480
Product use issue	13.90	11.92	45	34208	209777	79500358
Oedema peripheral	13.64	11.92	167	34086	252121	79458014
Injection site hypersensitivity	13.31	11.92	9	34244	1916	79708219
Blood pressure increased	13.26	11.92	144	34109	211216	79498919
Abdominal discomfort	13.23	11.92	59	34194	250668	79459467
Mobility decreased	13.20	11.92	20	34233	122155	79587980
Impaired healing	13.13	11.92	11	34242	87644	79622491
Dizziness	12.78	11.92	306	33947	526135	79184000
Acute myocardial infarction	12.67	11.92	66	34187	76970	79633165
Sinus disorder	12.57	11.92	29	34224	22435	79687700
Decreased insulin requirement	12.55	11.92	4	34249	147	79709988
Forced expiratory volume decreased	12.35	11.92	16	34237	7798	79702337
Device malfunction	12.34	11.92	28	34225	21420	79688715
Extradural haematoma	12.15	11.92	10	34243	2866	79707269
Injection site ulcer	12.11	11.92	6	34247	713	79709422
Exercise tolerance decreased	11.94	11.92	17	34236	9054	79701081

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10AE05	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES INSULINS AND ANALOGUES Insulins and analogues for injection, long-acting
FDA CS	M0011417	Insulin
FDA Chemical/Ingredient	N0000004931	Insulin
FDA EPC	N0000175453	Insulin Analog
MeSH PA	D007004	Hypoglycemic Agents
CHEBI has role	CHEBI:35526	antidiabetic
FDA EPC	N0000175944	Insulin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus	indication	73211009	DOID:9351

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Insulin receptor	Kinase	P06213	INSR_HUMAN	AGONIST				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D04539	KEGG_DRUG
4017559	VANDF
4017569	VANDF
4019786	VANDF
CHEBI:5931	CHEBI
CHEMBL2104391	ChEMBL_ID
DB01307	DRUGBANK_ID
DB00030	DRUGBANK_ID
139825	RXNORM
19234	MMSL
4885	MMSL
4886	MMSL
72333	MMSL
d00262	MMSL
d04369	MMSL
d05436	MMSL
000869	NDDF
000870	NDDF
006518	NDDF
010059	NDDF
126210001	SNOMEDCT_US
414515005	SNOMEDCT_US
414518007	SNOMEDCT_US
417423002	SNOMEDCT_US
420609005	SNOMEDCT_US
96367001	SNOMEDCT_US
D000069057	MESH_DESCRIPTOR_UI
C0537270	UMLSCUI
C0795635	UMLSCUI
7735	INN_ID
16137271	PUBCHEM_CID
5186	INN_ID
118984375	PUBCHEM_CID
4FT78T86XV	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	0169-3687	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	0169-3687	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	0169-3687	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	0169-6432	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	0169-6438	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	0169-6438	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	0169-6438	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1276	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1276	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1276	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1475	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1475	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1475	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4501	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
LEVEMIR	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6391	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	26 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6414	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	26 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5883	INJECTION, SOLUTION	14.20 mg	SUBCUTANEOUS	NDA	26 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	68258-8977	IMPLANT	14.20 mg	SOFT TISSUE	NDA	26 sections
Levemir	HUMAN PRESCRIPTION DRUG LABEL	1	70518-1462	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections